# Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors

> **NCT05039073** · PHASE2 · RECRUITING · sponsor: **Emory University** · enrollment: 46 (estimated)

## Conditions studied

- Recurrent Classic Hodgkin Lymphoma
- Refractory Classic Hodgkin Lymphoma

## Interventions

- **DRUG:** Brentuximab Vedotin
- **PROCEDURE:** Hematopoietic Cell Transplantation
- **BIOLOGICAL:** Nivolumab
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT05039073
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-02
- **Primary completion:** 2026-11-30
- **Final completion:** 2027-11-30
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2025-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05039073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05039073, "Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05039073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*